tetano
Editor, Senior Moderator
Cardiol Ther
. 2021 Jun 30.
doi: 10.1007/s40119-021-00232-8. Online ahead of print.
Cardiovascular Involvement in COVID-19: What Sequelae Should We Expect?
Maria Vincenza Polito[SUP] 1 [/SUP], Angelo Silverio[SUP] 2 [/SUP], Michele Bellino[SUP] 3 [/SUP], Giuseppe Iuliano[SUP] 3 [/SUP], Marco Di Maio[SUP] 3 [/SUP], Carmine Alfano[SUP] 3 [/SUP], Patrizia Iannece[SUP] 4 [/SUP], Nicolino Esposito[SUP] 1 [/SUP], Gennaro Galasso[SUP] 3 [/SUP]
Affiliations
Abstract
Several forms of cardiovascular involvement have been described in patients with Coronavirus disease 19 (COVID-19): myocardial injury, acute coronary syndrome, acute heart failure, myocarditis, pericardial diseases, arrhythmias, takotsubo syndrome, and arterial and venous atherothrombotic and thromboembolic events. Data on long-term outcome of these patients are still sparse, and the type and real incidence of cardiovascular sequelae are poorly known. It is plausible that myocardial injury may be the initiator of an inflammatory cascade, edema, and subsequent fibrosis, but also a consequence of systemic inflammation. The extent and distribution of ongoing inflammation may be the basis for ventricular dysfunction and malignant arrhythmias. Indeed, preliminary observational findings seem to emphasize the importance of close monitoring of COVID-19 patients with myocardial injury after discharge. Residual subclinical disease may be effectively investigated by using second-level imaging modalities such as cardiac magnetic resonance, which allows better characterization of the type and extension of myocardial damage, as well as of the ongoing inflammation after the acute phase. In patients with venous thromboembolism, a very common complication of COVID-19, the type and the duration of anticoagulation therapy after the acute phase should be tailored to the patient and based on the estimation of the individual thromboembolic and hemorrhagic risk. Large randomized clinical trials are ongoing to address this clinical question. Whether the severity of cardiovascular involvement, the type of treatments adopted during the acute phase, and the hemodynamic response, may influence the long-term outcome of patients recovered from COVID-19 is unknown. An etiological diagnosis of myocardial injury during the hospitalization is the first step for an appropriate follow-up in these patients. After discharge, the screening for residual left and right ventricular dysfunction, arrhythmias, residual thrombosis, and myocardial scar should be considered on a case-by-case basis, whereas an active clinical surveillance is mandatory in any patient.
Keywords: Acute coronary syndromes; COVID-19; Coronavirus; Long-term outcome; Myocardial injury; Myocarditis; Pericarditis; Pulmonary embolism; SARS-CoV-2.
. 2021 Jun 30.
doi: 10.1007/s40119-021-00232-8. Online ahead of print.
Cardiovascular Involvement in COVID-19: What Sequelae Should We Expect?
Maria Vincenza Polito[SUP] 1 [/SUP], Angelo Silverio[SUP] 2 [/SUP], Michele Bellino[SUP] 3 [/SUP], Giuseppe Iuliano[SUP] 3 [/SUP], Marco Di Maio[SUP] 3 [/SUP], Carmine Alfano[SUP] 3 [/SUP], Patrizia Iannece[SUP] 4 [/SUP], Nicolino Esposito[SUP] 1 [/SUP], Gennaro Galasso[SUP] 3 [/SUP]
Affiliations
- PMID: 34191268
- DOI: 10.1007/s40119-021-00232-8
Abstract
Several forms of cardiovascular involvement have been described in patients with Coronavirus disease 19 (COVID-19): myocardial injury, acute coronary syndrome, acute heart failure, myocarditis, pericardial diseases, arrhythmias, takotsubo syndrome, and arterial and venous atherothrombotic and thromboembolic events. Data on long-term outcome of these patients are still sparse, and the type and real incidence of cardiovascular sequelae are poorly known. It is plausible that myocardial injury may be the initiator of an inflammatory cascade, edema, and subsequent fibrosis, but also a consequence of systemic inflammation. The extent and distribution of ongoing inflammation may be the basis for ventricular dysfunction and malignant arrhythmias. Indeed, preliminary observational findings seem to emphasize the importance of close monitoring of COVID-19 patients with myocardial injury after discharge. Residual subclinical disease may be effectively investigated by using second-level imaging modalities such as cardiac magnetic resonance, which allows better characterization of the type and extension of myocardial damage, as well as of the ongoing inflammation after the acute phase. In patients with venous thromboembolism, a very common complication of COVID-19, the type and the duration of anticoagulation therapy after the acute phase should be tailored to the patient and based on the estimation of the individual thromboembolic and hemorrhagic risk. Large randomized clinical trials are ongoing to address this clinical question. Whether the severity of cardiovascular involvement, the type of treatments adopted during the acute phase, and the hemodynamic response, may influence the long-term outcome of patients recovered from COVID-19 is unknown. An etiological diagnosis of myocardial injury during the hospitalization is the first step for an appropriate follow-up in these patients. After discharge, the screening for residual left and right ventricular dysfunction, arrhythmias, residual thrombosis, and myocardial scar should be considered on a case-by-case basis, whereas an active clinical surveillance is mandatory in any patient.
Keywords: Acute coronary syndromes; COVID-19; Coronavirus; Long-term outcome; Myocardial injury; Myocarditis; Pericarditis; Pulmonary embolism; SARS-CoV-2.